We Think Zentalis Pharmaceuticals Needs To Drive Business Growth Carefully

ZNTL Stock  USD 2.15  0.03  1.42%   
About 51% of Zentalis Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Zentalis Pharmaceuticals Llc suggests that many traders are impartial. Zentalis Pharmaceuticals' investing sentiment shows overall attitude of investors towards Zentalis Pharmaceuticals Llc.
  
Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Read at simplywall.st
Simply Wall St News at Macroaxis
  

Zentalis Pharmaceuticals Fundamental Analysis

We analyze Zentalis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zentalis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zentalis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Flow From Operations

Cash Flow From Operations Comparative Analysis

Zentalis Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Zentalis Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zentalis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Zentalis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zentalis Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Zentalis Pharmaceuticals Related Equities

DSGNDesign Therapeutics   3.27   
0%
19.0%
PTGXProtagonist Therapeutics   3.02   
0%
18.0%
SNDXSyndax Pharmaceuticals   2.17   
0%
13.0%
INZYInozyme Pharma   1.68   
0%
10.0%
ITOSIteos Therapeutics   1.29   
0%
7.0%
ANNXAnnexon   0.78   
0%
4.0%
BPMCBlueprint Medicines   0.15   
0%
1.0%
ERASErasca   0.71   
4.0%
0%
GLUEMonte Rosa   1.03   
6.0%
0%
OLMAOlema Pharmaceuticals   1.29   
7.0%
0%
CGEMCullinan Oncology   1.29   
7.0%
0%
KYMRKymera Therapeutics   1.70   
10.0%
0%
RVMDRevolution Medicines   2.03   
12.0%
0%
SANASana Biotechnology   10.07   
61.0%
0%
DAWNDay One   16.50   
100.0%
0%
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.